GlassScriptPhysician profile
Sanober Parveen
NPI 1467894527
$482.16
in general payments reported to CMS, 2019-2025
9 companies · $84.22 in 2025
The $84.22 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $15.72 · 2022: $56.80 · 2023: $99.73 · 2024: $65.23 · 2025: $84.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $145.66 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Medtronic, INC. | $83.69 | 2023-2024 | Minimed 780g |
| Corcept Therapeutics | $56.80 | 2022 | |
| Medtronic Minimed, INC. | $35.46 | 2019 | |
| Insulet Corporation | $27.20 | 2023 | Omnipod |
| Amgen INC. | $17.96 | 2024 | Evenity |
| Ultragenyx Pharmaceutical INC. | $15.72 | 2020 | |
| Mannkind Corporation | $15.45 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanober Parveen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.